{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:38:33Z","timestamp":1784907513660,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"am","delay-in-days":321,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.lungcan.2022.01.003","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T03:25:43Z","timestamp":1641439543000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I\/II clinical trial"],"prefix":"10.1016","volume":"165","author":[{"given":"Mario","family":"Ghosn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waseem","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Livschitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Maybody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz E.","family":"Boas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DaeHee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Beattie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Offin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie W.","family":"Rusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie G.","family":"Zauderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lungcan.2022.01.003_b0005","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2022.01.003_b0010","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.lungcan.2022.01.003_b0015","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"261","key":"10.1016\/j.lungcan.2022.01.003_b0020","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2022.01.003_b0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.lungcan.2022.01.003_b0030","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lungcan.2022.01.003_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2021.06.006","article-title":"Imaging CAR T-cell kinetics in solid tumors: translational implications","author":"Skovgard","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"issue":"11","key":"10.1016\/j.lungcan.2022.01.003_b0040","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41551-021-00821-x","article-title":"Arming T cells to infiltrate pancreatic tumours","volume":"5","author":"Cherkassky","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"4","key":"10.1016\/j.lungcan.2022.01.003_b0045","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/mt.2009.309","article-title":"A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions","volume":"18","author":"Sterman","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lungcan.2022.01.003_b0050","doi-asserted-by":"crossref","unstructured":"L.M. Krug, M.G. Zauderer, P.S. Adusumili, E. McGee, K. Sepkowitz, M. Klang, Y.A. Yu, P. Scigalla, V.W. Rusch, Phase I study of intra-pleural administration of GL-ONC1, an oncolytic vaccinia virus, in patients with malignant pleural effusion, J. Clin. Oncol. 33(15_suppl) (2015) 7559-7559. 10.1200\/jco.2015.33.15_suppl.7559.","DOI":"10.1200\/jco.2015.33.15_suppl.7559"},{"issue":"226","key":"10.1016\/j.lungcan.2022.01.003_b0055","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2022.01.003_b0060","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2022.01.003_b0065","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/crj.13010","article-title":"Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy","volume":"13","author":"Murthy","year":"2019","journal-title":"Clin. Respir. J."},{"issue":"5","key":"10.1016\/j.lungcan.2022.01.003_b0070","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.ymthe.2018.02.015","article-title":"Phase I study of intrapleural gene-mediated cytotoxic immunotherapy in patients with malignant pleural effusion","volume":"26","author":"Aggarwal","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lungcan.2022.01.003_b0075","doi-asserted-by":"crossref","unstructured":"D.H. Sterman, E. Alley, J.P. Stevenson, J. Friedberg, S. Metzger, A. Recio, E.K. Moon, A.R. Haas, A. Vachani, S.I. Katz, J. Sun, D.F. Heitjan, W.T. Hwang, L. Litzky, J.H. Yearley, K.S. Tan, E. Papasavvas, P. Kennedy, L.J. Montaner, K.A. Cengel, C.B. Simone, 2nd, M. Culligan, C.J. Langer, S.M. Albelda, Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-ifnalpha combined with chemotherapy, Clin Cancer Res. 22(15) (2016) 3791-800. 10.1158\/1078-0432.CCR-15-2133.","DOI":"10.1158\/1078-0432.CCR-15-2133"},{"issue":"26","key":"10.1016\/j.lungcan.2022.01.003_b0080","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2022.01.003_b0085","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lungcan.2022.01.003_b0090","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","author":"Vitanza","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2022.01.003_b0095","doi-asserted-by":"crossref","unstructured":"P.S. Adusumilli, M.G. Zauderer, I. Riviere, S.B. Solomon, V.W. Rusch, R.E. O'Cearbhaill, A. Zhu, W. Cheema, N.K. Chintala, E. Halton, J. Pineda, R. Perez-Johnston, K.S. Tan, B. Daly, J.A. Araujo Filho, D. Ngai, E. McGee, A. Vincent, C. Diamonte, J.L. Sauter, S. Modi, D. Sikder, B. Senechal, X. Wang, W.D. Travis, M. Gonen, C.M. Rudin, R.J. Brentjens, D.R. Jones, M. Sadelain, A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab, Cancer Discov. 11(11) (2021) 2748-2763. 10.1158\/2159-8290.CD-21-0407.","DOI":"10.1158\/2159-8290.CD-21-0407"},{"issue":"5","key":"10.1016\/j.lungcan.2022.01.003_b0100","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.rcl.2015.05.007","article-title":"Image-guided percutaneous abdominal mass biopsy: technical and clinical considerations","volume":"53","author":"Lipnik","year":"2015","journal-title":"Radiol. Clin. North Am."},{"key":"10.1016\/j.lungcan.2022.01.003_b0105","doi-asserted-by":"crossref","unstructured":"A.L. Tam, E.S. Kim, J.J. Lee, J.E. Ensor, M.E. Hicks, X. Tang, G.R. Blumenschein, C.M. Alden, J.J. Erasmus, A. Tsao, S.M. Lippman, W.K. Hong, Wistuba, II, S. Gupta, Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial, J. Thorac. Oncol. 8(4) (2013) 436\u2013442. 10.1097\/JTO.0b013e318287c91e.","DOI":"10.1097\/JTO.0b013e318287c91e"},{"issue":"9366","key":"10.1016\/j.lungcan.2022.01.003_b0110","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0140-6736(03)13079-6","article-title":"Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial","volume":"361","author":"Maskell","year":"2003","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.lungcan.2022.01.003_b0115","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrclinonc.2010.155","article-title":"Clinical utility of image-guided peritoneal and omental biopsy","volume":"7","author":"Spencer","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2022.01.003_b0120","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.7911","article-title":"Assessment of image-guided intratumoral delivery of immunotherapeutics in patients with cancer","volume":"3","author":"Sheth","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"9","key":"10.1016\/j.lungcan.2022.01.003_b0125","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.3390\/cancers12092567","article-title":"The landscape of CAR-T cell clinical trials against solid tumors- a comprehensive overview","volume":"12","author":"Schaft","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.lungcan.2022.01.003_b0130","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1158\/1078-0432.CCR-19-4073","article-title":"Interventional radiology for local immunotherapy in oncology","volume":"27","author":"Tselikas","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.lungcan.2022.01.003_b0135","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3390\/vaccines9050525","article-title":"Long-term follow-up of mesothelioma patients treated with dendritic cell therapy in three phase I\/II trials","volume":"9","author":"Dumoulin","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.lungcan.2022.01.003_b0140","doi-asserted-by":"crossref","unstructured":"R.A. Belderbos, P. Baas, R. Berardi, R. Cornelissen, D.A. Fennell, J.P. van Meerbeeck, A. Scherpereel, H. Vroman, J. Aerts, A multicenter, randomized, phase II\/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial, Transl. Lung Cancer Res. 8(3) (2019) 280-285. 10.21037\/tlcr.2019.05.05.","DOI":"10.21037\/tlcr.2019.05.05"},{"issue":"5","key":"10.1016\/j.lungcan.2022.01.003_b0145","first-page":"402","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2022.01.003_b0150","doi-asserted-by":"crossref","unstructured":"J. Dozier, H. Zheng, P.S. Adusumilli, Immunotherapy for malignant pleural mesothelioma: current status and future directions, Transl. Lung Cancer Res. 6(3) (2017) 315-324. 10.21037\/tlcr.2017.05.02.","DOI":"10.21037\/tlcr.2017.05.02"},{"issue":"6","key":"10.1016\/j.lungcan.2022.01.003_b0155","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.lungcan.2022.01.003_b0160","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2021.05.004","article-title":"CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials","volume":"157","author":"Chintala","year":"2021","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2022.01.003_b0165","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/JTO.0b013e31815608d9","article-title":"Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center","volume":"2","author":"Flores","year":"2007","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2022.01.003_b0170","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1148\/rg.346130089","article-title":"Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma","volume":"34","author":"Nickell","year":"2014","journal-title":"Radiographics"},{"issue":"11","key":"10.1016\/j.lungcan.2022.01.003_b0175","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1093\/annonc\/mdy423","article-title":"Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)","volume":"29","author":"Marabelle","year":"2018","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2022.01.003_b0180","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jvir.2010.01.011","article-title":"Quality improvement guidelines for percutaneous needle biopsy","volume":"21","author":"Gupta","year":"2010","journal-title":"J. Vasc. Interv. Radiol."},{"issue":"3","key":"10.1016\/j.lungcan.2022.01.003_b0185","doi-asserted-by":"crossref","first-page":"W110","DOI":"10.2214\/AJR.17.18014","article-title":"Ultrasound guidance versus CT guidance for peripheral lung biopsy: performance according to lesion size and pleural contact","volume":"210","author":"Lee","year":"2018","journal-title":"AJR Am. J. Roentgenol."},{"issue":"3","key":"10.1016\/j.lungcan.2022.01.003_b0190","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1148\/radiol.12112077","article-title":"Pleural and peripheral lung lesions: comparison of US- and CT-guided biopsy","volume":"266","author":"Sconfienza","year":"2013","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.lungcan.2022.01.003_b0195","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.2214\/AJR.09.2532","article-title":"Imaging of thoracic lymphatic diseases","volume":"193","author":"Raman","year":"2009","journal-title":"AJR Am. J. Roentgenol."},{"issue":"1108","key":"10.1016\/j.lungcan.2022.01.003_b0200","doi-asserted-by":"crossref","first-page":"20190866","DOI":"10.1259\/bjr.20190866","article-title":"Pneumothorax rates in CT-guided lung biopsies: a comprehensive systematic review and meta-analysis of risk factors","volume":"93","author":"Huo","year":"2020","journal-title":"Br. J. Radiol."},{"issue":"2","key":"10.1016\/j.lungcan.2022.01.003_b0205","doi-asserted-by":"crossref","first-page":"W215","DOI":"10.2214\/AJR.13.10572","article-title":"FDG PET\/CT in the management of primary pleural tumors and pleural metastases","volume":"201","author":"Kruse","year":"2013","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.lungcan.2022.01.003_b0210","doi-asserted-by":"crossref","unstructured":"J.L. Galeano Ni\u00f1o, S.V. Pageon, S.S. Tay, F. Colakoglu, D. Kempe, J. Hywood, J.K. Mazalo, J. Cremasco, M.A. Govendir, L.F. Dagley, K. Hsu, S. Rizzetto, J. Zieba, G. Rice, V. Prior, G.M. O'Neill, R.J. Williams, D.R. Nisbet, B. Kramer, A.I. Webb, F. Luciani, M.N. Read, M. Biro, Cytotoxic T cells swarm by homotypic chemokine signalling, eLife 9 (2020) e56554. 10.7554\/eLife.56554.","DOI":"10.7554\/eLife.56554"},{"issue":"11","key":"10.1016\/j.lungcan.2022.01.003_b0215","doi-asserted-by":"crossref","first-page":"eaal1713","DOI":"10.1126\/sciimmunol.aal1713","article-title":"Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells","volume":"2","author":"Dai","year":"2017","journal-title":"Sci. Immunol."},{"issue":"5","key":"10.1016\/j.lungcan.2022.01.003_b0220","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.lungcan.2022.01.003_b0225","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001800","article-title":"Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy","volume":"9","author":"Munoz","year":"2021","journal-title":"J. ImmunoTher. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2022.01.003_b0230","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.lungcan.2022.01.003_b0235","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222000034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222000034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:54:00Z","timestamp":1759236840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222000034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":47,"alternative-id":["S0169500222000034"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.01.003","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I\/II clinical trial","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}